Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.35M Buy
20,100
+700
+4% +$46.6K ﹤0.01% 2204
2026
Q1
$1.22M Sell
19,400
-6,100
-24% -$425K ﹤0.01% 2224
2025
Q4
$1.69M Buy
25,500
+17,200
+207% +$1.11M ﹤0.01% 1925
2025
Q3
$559K Sell
8,300
-33,700
-80% -$2.67M ﹤0.01% 2635
2025
Q2
$3.67M Buy
42,000
+25,800
+159% +$2.02M 0.01% 1279
2025
Q1
$1.11M Buy
16,200
+13,300
+459% +$1.09M ﹤0.01% 1753
2024
Q4
$226K Buy
+2,900
New +$215K ﹤0.01% 2760
2024
Q3
Sell
-22,700
Closed -$2.57M 2801
2024
Q2
$2.57M Buy
+22,700
New +$2.87M 0.01% 941
2024
Q1
Sell
-3,500
Closed -$434K 2349
2023
Q4
$434K Sell
3,500
-11,500
-77% -$1.17M ﹤0.01% 1860
2023
Q3
$1.4M Buy
15,000
+5,100
+52% +$575K 0.01% 1117
2023
Q2
$1.27M Buy
9,900
+7,600
+330% +$919K 0.02% 1169
2023
Q1
$268K Sell
2,300
-4,900
-68% -$549K ﹤0.01% 2010
2022
Q4
$814K Buy
+7,200
New +$790K 0.02% 1253
2022
Q3
Sell
-5,200
Closed -$388K 2402
2022
Q2
$388K Buy
+5,200
New +$475K 0.01% 1415

Other funds holding DXCM

Paul Tudor Jones's DXCM Position: Q1 2026 in Review

Paul Tudor Jones sold out of DexCom (DXCM) in Q1 2026, closing a stake of 24,004 shares — an estimated $1.67M sold.

Paul Tudor Jones first reported a position in DXCM in Q4 2013 and held it in 22 quarters. The position peaked at $4.81M in Q4 2023. 960 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Paul Tudor Jones reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 24,004 DexCom shares in Q1 2026, an estimated $1.67M.
  • Paul Tudor Jones first reported a position in DexCom in Q4 2013 and held it in 22 quarters.
  • Paul Tudor Jones's DexCom position peaked at $4.81M in Q4 2023.
  • 960 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.